Genomic Testing in Breast Cancer: Clinical Applications and Best Practices - Episode 8
Leveraging TAILORx Findings to Guide Testing and Treatment Decisions in Node-Negative Breast Cancer
Panelists discuss how the TAILORx trial data were transformative for estrogen receptor–positive breast cancer by establishing clearer thresholds for chemotherapy benefit, while raising important questions about whether younger patients with intermediate scores benefit from chemotherapy itself or from the ovarian suppression it causes.
TAILORx Trial Impact and Evolving Treatment Approaches
Main Discussion Topics:
- Interpretation of TAILORx data in treatment planning
- Chemotherapy regimen selection based on recurrence score
- Potential role of ovarian suppression vs chemotherapy in premenopausal patients
Key Points for Physicians:
- TAILORx transformed the interpretation of the 21-gene assay by providing clearer guidance for the intermediate-risk group.
- Higher recurrence scores may still warrant consideration of anthracycline-containing regimens.
- The NRG-BROO9 trial is investigating whether ovarian suppression rather than chemotherapy drives benefit in premenopausal patients.
Notable Insights:
- There is a broader trend toward reducing cytotoxic chemotherapy use across breast cancer subtypes.
- Despite advances in early-stage disease management, a significant proportion of breast cancer deaths occur in patients initially diagnosed with stage I-II disease.
Clinical Significance: TAILORx data have clarified treatment approaches for intermediate-risk scores, but questions remain about optimal chemotherapy regimens and whether ovarian suppression could replace chemotherapy in select premenopausal patients.
Related Content:
